Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,168,519 papers from all fields of science
Search
Sign In
Create Free Account
CPNE3 gene
Known as:
CPNE3
, copine 3
, CPN3
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
CPNE3 promotes migration and invasion in non-small cell lung cancer by interacting with RACK1 via FAK signaling activation
He-chun Lin
,
X. Zhang
,
+8 authors
M. Yao
Journal of Cancer
2018
Corpus ID: 53701806
Approximately 90% of patients diagnosed with non-small cell lung cancer (NSCLC) die due to distant metastases. However, the…
Expand
2017
2017
High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia
L. Fu
,
Huaping Fu
,
+8 authors
Jinlong Shi
Cancer Science
2017
Corpus ID: 30038391
CPNE3, a member of a Ca2+‐dependent phospholipid‐binding protein family, was identified as a ligand of ERBB2 and has a more…
Expand
2013
2013
Low CPNE3 expression is associated with risk of acute myocardial infarction: A feasible genetic marker of acute myocardial infarction in patients with stable coronary artery disease
Buchuan Tan
,
Long Liu
,
Yushuang Yang
,
Qian Liu
,
Liping Yang
,
Fanbo Meng
Cardiology Journal
2013
Corpus ID: 22972526
Background Gene COPINE III may be related to a phosphoprotein with intrinsic kinase activity and belongs to an unconventional…
Expand
2000
2000
Characterization of human copine III as a phosphoprotein with associated kinase activity.
E. Caudell
,
James J. Caudell
,
Chi-Hui Tang
,
Tse-Kuan Yu
,
Mitchell J. Frederick
,
Elizabeth A. Grimm
Biochemistry
2000
Corpus ID: 25699734
The copines, first described by Creutz et al. [(1998) J. Biol. Chem. 273, 1393-1402], comprise a two C2 domain-containing protein…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE